AhmedElkhananyMD(He/Him)

Oncology • Houston, TX

Breast Cancer

Assistant Professor of Medicine at BCM

Join to view full profile

Dr. Elkhanany is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Elkhanany's full profile

Already have an account?

Office
2525A Holly Hall St
Houston, TX 77054
Phone+1 713-566-3757

Summary

Dr. Ahmed Elkhanany is a Houston-based oncology specialist with a subspecialty in breast cancer, currently serving as an Assistant Professor at Baylor College of Medicine. After receiving his initial education from Alexandria University, he completed his residency in internal medicine at the University of Missouri-Kansas City School of Medicine, and earned a fellowship in hematology and medical oncology at Roswell Park Comprehensive Cancer Center. Dr. Elkhanany also completed a postdoctoral fellowship at Mayo Clinic College in the Breast Cancer Translational Group. He has a wealth of experience in numerous areas of breast cancer, including immunotherapy, genomics, and novel therapeutics; along with a significant number of publications and clinical trials attached to his name. Recognized for his outstanding work, in 2015 he was honored as a Gold Humanism Honor Member by the Gold Humanism Honor Society.

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2016 - 2019
University of Missouri-Kansas City School of MedicineResidency, Internal Medicine, 2013 - 2016
Mayo Clinic College of MedicinePost-Doctoral Fellowship, 2012 - 2013
Alexandria University Faculty of MedicineClass of 2011

Certifications & Licensure

TX State Medical License 2023 - 2025
AL State Medical License 2019 - 2023
NY State Medical License 2016 - 2018
MO State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Harvard Business SchoolHealth Care Leadership

Awards, Honors, & Recognition

Gold Humanism Honor Member Gold Humanism Honor Society, 2015

Clinical Trials

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer Start of enrollment: 2018 Dec 07
Active, not recruiting
Phase 3
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Start of enrollment: 2019 Jul 08
Recruiting
Phase 2
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer Start of enrollment: 2018 Nov 13
Active, not recruiting
Phase 2
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer Start of enrollment: 2021 Sep 15
Active, not recruiting
Phase 1, Phase 2
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy Start of enrollment: 2020 Mar 13
Recruiting
Phase 2
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2019 Aug 28
Enrolling by invitation
Phase 2
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers Start of enrollment: 2023 Mar 21
Active, not recruiting
Phase 1, Phase 2
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Recruiting
Phase 3
STOP-HER2: Stopping Trastuzumab in HER2+ MBC Start of enrollment: 2023 Apr 19
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer Start of enrollment: 2023 Nov 27
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

51 citations
Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion.
Song Yao, Tongguang Cheng, Ahmed Elkhanany, Li Yan, Angela Omilian
Journal of the National Cancer Institute. 2021-08-02
581 citations
Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021
Mary B. Daly, Tuya Pal, Michael Berry, Saundra S. Buys, Patricia I. Dickson
Journal of the National Comprehensive Cancer Network. 2021-01-06
62 citations
GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways.
Santanu Bhattacharya, Krishnendu Pal, Anil K. Sharma, Shamit K. Dutta, Julie S. Lau
Plos One. 2014-12-03

Abstracts/Posters

Older Patients with NPM1 Mutated AML Have Distinctive Genomic Mutation Landscape Associated with Enrichment in Immunosuppressive Gene Signature
Ahmad Elkhanany, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Biological Drivers of Progression in ER+ Metastatic Breast Cancer
OncLive - 6/15/2023
Racial disparity in breast cancer immune microenvironment.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018